Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 21Head & Neck 4Thoracic 3Sarcoma 2Gynecologic 2Genitourinary 2Breast 2Dermatologic 1CNS 1

Conditions

Breast Neoplasms 196Triple Negative Breast Neoplasms 26Neoplasm Metastasis 18Breast Neoplasms, Male 13Ovarian Neoplasms 9Inflammatory Breast Neoplasms 9Pancreatic Neoplasms 8Neoplasms 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Stomach Neoplasms 5Prostatic Neoplasms 4Lung Neoplasms 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Recurrence 2Multiple Myeloma 2Lymphedema 2Hematologic Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Uterine Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1

Interventions

pembrolizumab 18Trastuzumab 7Docetaxel 7Paclitaxel 6Magnetic Resonance Spectroscopy 5Taxes 4Drug Therapy 4Carboplatin 4Specimen Handling 3Psychiatric Rehabilitation 3Polymerase Chain Reaction 3Nivolumab 3Injections 3Fluorouracil 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Cisplatin 3Capecitabine 3Biopsy 3poly ICLC 2fludarabine 2durvalumab 2belinostat 2atezolizumab 2Radiotherapy 2Oxaliplatin 2Leucovorin 2Lapatinib 2Irinotecan 2Interleukin-12 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Bevacizumab × Breast × Clear all
NCT05005403 2026-05-13

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

AbbVie

Phase 1 Recruiting
694 enrolled
BreastGastrointestinalHead & NeckThoracic

Anophthalmia with pulmonary hypoplasia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡